Blokiuret

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blokiuret

What is Blokiuret? Defining a Fixed-Dose Antihypertensive

Property Description
Active ingredients Atenolol, Chlorthalidone
Form Oral Tablet (Comprimido)
Pharmacological class Antihypertensive Agent
Common use Control of High Blood Pressure (Hypertension)
Origin Synthetic Compounds

Blokiuret is a prescription-only medication classified as an antihypertensive agent, delivered as an oral tablet (comprimido), designed to manage high blood pressure (hypertension). This product represents a fixed-dose combination of two distinct, synthetic active ingredients, strategically paired to provide a robust, dual-pathway approach to blood pressure control. This specific combination is a clinically recognized standard of care for initiating or maintaining treatment in patients requiring more than one agent to achieve blood pressure goals.


What Type of Medicine is Blokiuret? (Identity and Class)

Blokiuret is a combination medicine that unites two major pharmacological classes in a single oral dosage form. This fixed-dose combination is definitively categorized as an antihypertensive agent because its overarching purpose is the effective reduction of pressure within the arteries. This dual-agent formulation is typically positioned for patients who have not achieved adequate control using a single antihypertensive agent alone. Both active components, Atenolol and Chlorthalidone, are chemically synthetic compounds. The consolidation of two distinct therapeutic mechanisms into one pill simplifies the complex, long-term regimen often required for managing chronic hypertension.


What is Blokiuret’s Composition? (The Dual Active Ingredients)

The medication contains two active ingredients with complementary actions: Atenolol and Chlorthalidone. Atenolol is a beta-blocker, specifically a cardioselective beta1-selective beta-blocker, which targets receptors primarily in the heart. Chlorthalidone is a thiazide-like diuretic, often utilized for its effectiveness in the sustained treatment of blood pressure. The pharmaceutical form is an oral tablet, which includes necessary solid pharmaceutical excipients to ensure stability and proper delivery.


What is the General Purpose of Blokiuret? (High-Level Benefit)

The general purpose of Blokiuret is to achieve effective and reliable control of hypertension through a synergistic dual mechanism of action. The Atenolol component reduces the strain on the cardiovascular system by decreasing the rate and force of the heart's pumping action. Concurrently, the Chlorthalidone component promotes diuresis (increased urination) and the increased excretion of salt, resulting in a reduction of the total fluid volume in the bloodstream. This combined physiological effect provides a comprehensive strategy to manage arterial pressure, offering sustained relief from the chronic burden of high blood pressure, particularly in scenarios where fluid retention may be a complicating factor.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Blokiuret?

Possible Side Effects and Safety Information

The official safety profile for Blokiuret, a fixed-dose combination of Atenolol (a beta-blocker) and Chlorthalidone (a thiazide-like diuretic), is defined by reactions across several physiological systems as documented in regulatory sources.

Adverse reactions are classified by frequency, with Common effects including bradycardia (slow heart rate), fatigue, lethargy, dizziness, and various gastrointestinal upsets.

System-Organ Class (SOC) Documented Effects
Cardiovascular Bradycardia, hypotension, heart block
Nervous System Dizziness, lethargy, sleep disturbances
Metabolism/Nutrition Electrolyte imbalances (e.g., hypokalemia), hyperglycemia

Regulatory labeling highlights specific Serious Adverse Reactions and constraints. Use is strictly contraindicated in conditions such as overt cardiac failure, cardiogenic shock, anuria (no urine production), and second or third-degree heart block. Due to the Chlorthalidone component, the medicine is also prohibited in patients with known hypersensitivity to sulfonamide-derived drugs.

Population-specific safety notes require caution in patients with hepatic impairment and state that the drug is contraindicated in severe renal failure and during pregnancy. A critical time-related pattern is the warning that abrupt cessation of the beta-blocker component may result in the exacerbation of angina pectoris or precipitation of a myocardial infarction.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Blokiuret may present with serious physiological disturbances related to its active components. Documented manifestations include profound bradycardia (abnormally slow heart rate) and marked hypotension (low blood pressure). Due to the diuretic component, significant electrolyte disturbances, such as hypokalemia (low potassium) and hyponatremia (low sodium), are documented. Other signs may include somnolence, confusion, wheezing, and extreme weakness. Overdose can progress to life-threatening conditions, including circulatory collapse, cardiogenic shock, seizures, and coma.


When to Seek Emergency Help

Any suspected overdose of Blokiuret requires immediate medical attention. Regulatory authorities mandate that individuals seek emergency help immediately if severe symptoms such as collapse, unresponsiveness, or trouble breathing occur. It is required to contact a Poison Control Center at once. Management described in official sources is primarily symptomatic and supportive treatment, as no specific antidote is known. Procedures to limit absorption, such as gastric lavage or administration of activated charcoal, may be employed in a clinical setting. Pediatric overdose cases carry an increased risk of severe hypoglycemia (low blood sugar).

Therapeutic Uses of Blokiuret

What Blokiuret Treats: Main Uses and Benefits

Blokiuret contains the active ingredient bendroflumethiazide, a type of thiazide diuretic primarily used in the management of two major conditions: high blood pressure (essential hypertension) and edema (fluid retention). This medication is used to assist in managing fluid buildup in the body and assist in blood pressure management.

Its diuretic effect is commonly utilized to manage swelling, particularly in the ankles and legs, providing symptomatic support for those conditions. Bendroflumethiazide is indicated for the treatment of essential hypertension and for edema associated with conditions such as congestive heart failure, nephrotic syndrome, and cirrhosis of the liver. This treatment is part of a broader management plan for high blood pressure.

“The primary therapeutic goal is to assist in managing fluid levels and blood pressure.”


Quick Fact: Focus on Fluid Retention

Eligibility and Restrictions for Use

Blokiuret's eligibility profile is strictly defined by regulatory authorities for the Adult Population seeking management of hypertension. The medicine is not recommended for the pediatric population (children and adolescents) as its safety and efficacy have not been established in this age group.

Absolute Contraindications prohibit the use of Blokiuret in patients with specific severe conditions. These exclusions include Sinus Bradycardia, Heart Block greater than first degree, Cardiogenic Shock, and Overt/Uncontrolled Cardiac Failure. Non-cardiac contraindications also include Anuria (no urine formation), Severe Renal Impairment, and known Hypersensitivity to the active components or any sulfonamide-derived drugs.

Use is contraindicated during both Pregnancy and Lactation. Furthermore, use requires caution in patients with conditions such as Impaired Hepatic Function, Bronchospastic Disorders (e.g., asthma), Diabetes Mellitus, untreated Pheochromocytoma, or pre-existing Hypokalaemia.

What should I know about interactions with other medicines?

This section describes officially documented interaction patterns for Blokiuret as specified in government regulatory sources.

Drug-Drug and Substance Interactions

Co-administration of Blokiuret with other medicines can result in either additive effects or altered exposure of certain substances.

Interaction Type Interacting Agents Officially Documented Outcome
Additive Pharmacodynamic Other Antihypertensives, Alcohol Enhanced hypotensive effect is documented.
Pharmacodynamic/Cardiac Verapamil, Diltiazem (IV), Digitalis Glycosides Increased risk of severe hypotension or potentiation of effects on AV conduction.
Exposure Alteration Lithium The Chlorthalidone component reduces the renal clearance of Lithium, potentially leading to elevated plasma concentrations.
Antagonistic Effect Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs are documented to antagonise the diuretic effect of Chlorthalidone.

Interaction-Related Restrictions and Timing Rules

Certain combinations are restricted due to the severity of the documented interaction. The intravenous co-administration of Verapamil or Diltiazem is classified as a contraindicated combination with the Atenolol component. Furthermore, administration of Aluminum Hydroxide (antacid) requires a mandatory two-hour separation from Blokiuret to avoid documented interference with the absorption of the Atenolol component.

Population-Specific Interaction Considerations

Specific interaction cautions apply to certain populations as noted in the label. The concomitant use of Aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment with a GFR below 60 mL/min/1.73 m^2.

Mechanism of Action

Blokiuret functions as a selective modulator of bone turnover by influencing the Wnt signaling cascade. The compound exhibits binding specificity for the LRP5 receptor, a co-receptor of the Wnt pathway located on the cell surface of osteoblasts. This interaction initiates a conformational change in the receptor complex, leading to the stabilization of beta-catenin within the cytoplasm. Consequently, Blokiuret acts as an inhibitor of the Wnt/beta-catenin signaling pathway.

The stabilized beta-catenin then translocates to the nucleus, where it affects downstream regulation of osteoblast differentiation and matrix deposition. The compound also modulates the signaling cascade that regulates osteoclast-mediated bone resorption, thus influencing the balance of bone turnover. This interaction subsequently modulates the transcriptional activity of target genes involved in bone remodeling.

Dosage and Administration Information

How to Use Blokiuret

Blokiuret is an oral, fixed-dose combination medication used in the long-term management of high blood pressure. The drug’s administration follows established high-level usage patterns. This medication is not indicated for initiating treatment but rather for maintaining or substituting an already established regimen using the individual components.


Official Administration Guidelines

Usage Parameter Instruction
Route of Administration The medication is taken by the oral route only.
Standard Dosing Schedule The typical regimen is once daily. The starting dose for the combination tablet is Atenolol 50 mg / Chlorthalidone 25 mg.
Timing for Administration Blokiuret may be taken without regard to food. To minimize disruption due to the diuretic component, administration is generally recommended in the morning or early afternoon.
Discontinuation When the medicine must be discontinued, the therapy must be withdrawn gradually over a period of approximately two weeks.

Population-Specific Use

Usage involves dose adjustment in patients with compromised renal function. If the creatinine clearance is below 35 mL/min/1.73 m^2, the dose of the Atenolol component is reduced to prevent accumulation. For example, the maximum dose for CrCl < 15 mL/min/1.73 m^2 is 50 mg Atenolol every other day. Furthermore, the safety and efficacy of Blokiuret have not been established for use in pediatric patients younger than 18 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blokiuret

Evidence for use in Essential Hypertension

Randomized Controlled Trials (RCTs) have explored the fixed-dose combination of Blokiuret in adult patients diagnosed with Essential Hypertension (High Blood Pressure). These studies were applied in research contexts involving fluctuating or unstable symptoms, where outcomes monitoring physiological strain or stress was crucial. Initial research monitored outcomes related to physiological strain, such as the measurement of changes in Systolic and Diastolic Blood Pressure (SBP and DBP) endpoints over defined time intervals.

Comparing Fixed-Dose Combination versus Individual Components

Comparative research was evaluated in studies designed to look at the combined pill versus regimens where patients took the two active ingredients in separate tablets. Studies explored these comparisons, particularly when managing conditions where symptoms may vary in intensity or require consistent, long-term observation. Post-marketing surveillance and retrospective cohort studies examined treatment patterns and reported on adherence outcomes, comparing the single fixed-dose tablet to regimens requiring two separate tablets.

Long-Term Evidence and Follow-up

The available research includes both short-term and longer-term observation periods. The initial, strict RCTs typically focused on research exploring short-term symptom changes over a defined time interval, often ranging from 4 to 16 weeks. However, subsequent observational surveillance studies and cohort studies monitored patient groups over intermediate and long-term durations, tracking outcomes reflecting daily functioning or activity level for periods that may extend up to five years.

Research has explored long-term clinical outcomes related to major cardiovascular events, such as stroke or myocardial infarction. However, direct evidence for this specific fixed-dose combination product's effect on these long-term endpoints is limited. Instead, the research context relies on extrapolation from the research on the individual drug classes involved, where the long-term outcomes are not fully established for the combination itself. This means that data for long-term outcomes are still emerging for this specific product.

What Research Gaps and Uncertainties Exist

The scientific record highlights several areas where evidence is limited or further research is ongoing. A key limitation is the fact that the follow-up durations were limited in many of the initial randomized trials, which means that the long-term durability of the blood pressure changes are not fully characterized. Additionally, there is limited information for long-term outcomes related to cardiovascular events that is specific to this fixed-dose combination, as data often relies on extrapolation from the individual drug classes.

Frequently Asked Questions (FAQ)

Common questions about Blokiuret (FAQ)

Q: Do I need to change my diet while taking Blokiuret?

A: Regulatory documents state that Blokiuret may be taken without regard to most food. However, official sources note that consuming large amounts of orange juice may moderately reduce the effectiveness of the atenolol component. A healthcare provider can provide specific guidance on long-term dietary changes, such as managing salt or potassium intake.

Q: What happens in the body if someone suddenly stops taking Blokiuret?

A: Official guidelines indicate that the medication is typically withdrawn gradually. Sudden discontinuation of the atenolol component has been reported to cause serious cardiac issues, such as angina (chest pain) or heart attack, especially in people with existing heart problems. This is why a gradual withdrawal process is described in the official prescribing information.

Q: Does Blokiuret have different effects based on a person's age?

A: Official information indicates that the safety and efficacy of Blokiuret have not been established for patients younger than 18 years. For adults, dose adjustments may be required based on kidney function. General age-based differences are not specifically detailed in the regulatory information for all adult populations.

Q: Are there any specific foods that are strictly prohibited with Blokiuret?

A: The official product information does not strictly prohibit most foods. However, specific regulatory notes advise caution regarding the consumption of large amounts of orange juice, as this may interfere with how the body absorbs the drug's atenolol component. The diuretic component may affect the balance of certain minerals in the blood, which often leads to monitoring.

Q: If a person feels better, should they continue taking Blokiuret as prescribed?

A: According to the official product information, Blokiuret is intended for the long-term management of chronic conditions, such as high blood pressure. Official guidance indicates that treatment typically continues as prescribed, even if the patient feels well, to maintain the necessary therapeutic effect.

Q: How long does it typically take for Blokiuret to start having an effect?

A: Regulatory documents state that a significant beta-blocking effect from the atenolol component is typically apparent within one hour after taking a single dose. The maximum effect is usually reached within a few hours. The full therapeutic benefit for the condition being treated is often observed after a longer duration.

Q: If I miss a dose of Blokiuret, will it affect how the medicine works overall?

A: If you miss a dose of Blokiuret and it is almost time for your next scheduled dose, regulatory guidelines indicate that the missed dose is typically skipped. The standard practice is to return to your normal schedule. Official sources advise against taking a double or extra dose to make up for the one that was missed.

Q: Can Blokiuret affect the results of common lab tests?

A: Official information indicates that Blokiuret can affect the results of certain common lab tests. For instance, the chlorthalidone component (a diuretic) may increase blood levels of triglycerides and cholesterol. This often results in the monitoring of blood glucose and serum potassium levels during treatment.

Q: Does Blokiuret have a known effect on sleep patterns?

A: The list of reported side effects in official documents may include disturbances in sleep patterns. This can manifest as vivid dreams, nightmares, or general trouble falling or staying asleep. If persistent sleep issues occur, consultation with a healthcare provider is recommended.

Q: Can people who are lactose intolerant take Blokiuret?

A: The official prescribing information contains a full list of all inactive ingredients, or excipients, in the tablet. This list may include ingredients like lactose, which are sometimes derived from common food allergens. Individuals with an intolerance are advised to consult the complete official ingredient list.

Q: Are there any specific supplements or vitamins that should be avoided with Blokiuret?

A: Regulatory documents advise caution with certain supplements. Official information notes that multivitamins containing minerals may decrease the blood-pressure-lowering effects of the atenolol component. Separation by at least two hours may be necessary. Blokiuret may also affect blood potassium levels.

Q: Does Blokiuret carry a Boxed Warning in the US?

A: The U.S. Food and Drug Administration (FDA) label for Blokiuret (Atenolol/Chlorthalidone combination) does not contain a Boxed Warning. A Boxed Warning is used by the FDA to highlight the most serious risks associated with a medicine.

Q: Can I take Blokiuret if I have an allergy to common medications?

A: Regulatory information advises against using Blokiuret if a patient has a known allergy to either active component (atenolol or chlorthalidone). Furthermore, the drug is often contraindicated for individuals with known allergies to sulfa-based medications, as the chlorthalidone component is a sulfonamide derivative.

Q: Is it normal to feel a specific sensation when first starting Blokiuret?

A: Official side effect reports list sensations that may be experienced when first starting the medication. These can include feeling dizzy, lightheaded, or unusually tired or weak. If these sensations are persistent or severe, review by a medical professional is indicated.

Q: Can Blokiuret be taken with over-the-counter pain relievers?

A: Official regulatory warnings indicate a possible interaction between Blokiuret and Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common over-the-counter pain relievers. NSAIDs may decrease the blood pressure lowering effects of the atenolol component, potentially reducing the overall effectiveness of Blokiuret.

Q: What are the official guidelines regarding Blokiuret use during pregnancy?

A: Official guidelines regarding Blokiuret use during pregnancy advise avoiding the drug unless the potential benefit justifies the risk to the fetus. The use of this drug has been reported to carry specific potential risks to the fetus or newborn, such as jaundice, low blood sugar (hypoglycemia), and low platelet count (thrombocytopenia).

Q: What is the physical appearance of the Blokiuret tablet or capsule?

A: The physical appearance of the Blokiuret tablet, including its shape, color, size, and imprint codes, is fully detailed in the product description section of the official prescribing information. This information is provided to help patients and providers confirm the correct medication.

Q: Does Blokiuret need special storage conditions?

A: Regulatory information specifies that Blokiuret is typically stored at room temperature, which is generally between 68 F and 77 F (20 C and 25 C). The medication is recommended to be protected from light and moisture and stored in a dry environment.

Q: Can people with a history of heart problems use Blokiuret?

A: Regulatory documents list specific cardiac conditions that are contraindications for the use of Blokiuret. These conditions include severe heart block, cardiogenic shock, and certain types of untreated heart failure, where the drug is generally contraindicated.

Q: Is it true that taking Blokiuret can cause dryness?

A: Official reports of side effects for the drug's components include symptoms related to dryness. Patients have reported experiencing dry mouth or dry eyes during treatment. These are typically listed among the commonly reported, less severe side effects.

Q: Can Blokiuret affect a person's ability to drive or operate machinery?

A: The official drug label includes a specific warning that the medication may affect a person's coordination, reaction time, or judgment. Caution regarding operating machinery or driving is generally recommended until the effects of the medication are fully known.

Q: What is the typical monitoring process a doctor uses while a patient is on Blokiuret?

A: According to regulatory sources, frequent monitoring is an expected part of the treatment process. This process typically involves frequent checks of blood pressure and blood tests to monitor parameters like blood sugar, serum potassium, and cholesterol levels.

Q: Does alcohol interact negatively with Blokiuret?

A: Official regulatory information recommends caution or avoidance of alcohol consumption while taking Blokiuret. Alcohol may enhance the drug's blood pressure lowering effects, leading to symptoms like dizziness, lightheadedness, or even fainting.

Q: Is Blokiuret a controlled substance?

A: Official regulatory information in the United States and other regions indicates that Blokiuret (the Atenolol/Chlorthalidone combination) is not classified as a controlled substance. This means it does not carry a specific schedule under the Controlled Substances Act (CSA).

Q: Does Blokiuret interact with herbal remedies?

A: The official prescribing information recommends informing healthcare providers about all products used, including vitamins and herbal remedies. This is generally recommended because some herbal products may interact with the drug's components.

Q: Where can I find the official prescribing information for Blokiuret?

A: Official sources provide clear instructions on where to find the complete regulatory documents. The full and current prescribing information, often referred to as the drug label, can be accessed through government websites like the U.S. DailyMed or the Food and Drug Administration (FDA).

How should Blokiuret be stored and disposed of?

How to Store and Dispose of Blokiuret

The official storage and disposal guidelines for Blokiuret (Atenolol and Chlorthalidone) are mandated by regulatory agencies to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep the container tightly closed and protect the tablets from light, moisture, and excessive heat.
Prohibition Do not freeze the medication. Do not store in high-humidity areas like a bathroom.
Safety Must be stored out of the reach and sight of children and pets.

Disposal Protocol

Expired or unused Blokiuret must not be discarded in the household trash or flushed down the toilet (wastewater). Patients should consult a pharmacist or local drug take-back program for the proper method of disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blokiuret found in:

A-Z Index: